
First Patient Imaged in Phase 3 AMPLIFY Trial for BCR of Prostate Cancer
The first patient has been imaged in the registrational phase 3 AMPLIFY (NCT06970847) trial of 64Cu-SAR-bisPSMA in patients with biochemical recurrence (BCR) of prostate cancer.1 64Cu-SAR-bisPSMA is a novel diagnostic that has demonstrated superiority …